ZURICH, Aug 23 (Reuters) - Lonza (LONN.S) is investing in new drug product manufacturing capacity at its site in Guangzhou, China, the Swiss company said on Monday. The sterile, multi-product fill and finish line is expected to be completed in 2022 and will create more than 150 jobs. Lonza, which has been making ingredients for Moderna"s (MRNA.O) COVID-19 vaccine, did not say how much it was spending on the Guangzhou plant.